News articles about Presbia PLC (NASDAQ:LENS) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Presbia PLC earned a news impact score of 0.14 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.
A number of research firms have recently issued reports on LENS. Zacks Investment Research lowered shares of Presbia PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, May 24th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Presbia PLC in a report on Tuesday, May 23rd. Finally, Rodman & Renshaw dropped their price objective on Presbia PLC from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, May 22nd. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $12.00.
Shares of Presbia PLC (NASDAQ:LENS) opened at 2.13 on Tuesday. The firm’s market cap is $36.12 million. Presbia PLC has a 52 week low of $1.86 and a 52 week high of $5.50. The stock has a 50 day moving average of $2.74 and a 200 day moving average of $3.12.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/07/18/presbia-plc-lens-getting-somewhat-favorable-press-coverage-study-finds-updated-updated.html.
Presbia PLC Company Profile
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.